Literature DB >> 15194538

Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?

Muriel Giansily-Blaizot1, Régis Verdier, Christine Biron-Adréani, Jean-François Schved, M A Bertrand, J Y Borg, V Le Cam-Duchez, V LeCam-Duchez, M E Briquel, H Chambost, K Pouymayou, F Dutrillaux, R Favier, I Martin-Toutain, E Verdy, V Gay, J Goudemand, R Navarro, A Durin, R d'Oiron, T Lambert, G Pernod, C Barrot, J Peynet, B Bastenaire, P Sie, N Stieltjes, M F Torchet, P de Moerloose.   

Abstract

BACKGROUND AND OBJECTIVES: Inherited factor VII (FVII) deficiency is a rare bleeding disorder characterized by a poor relationship between reported FVII clotting activity (FVII:C) and bleeding tendency. Our study was aimed at defining biological parameters that are possibly predictive for bleeding risk in this condition. DESIGN AND METHODS: Forty-two FVII-deficient patients (FVII:C <30%) were classified into two opposite clinical groups defined as severe and non-or-mild bleeders. For each patient, plasma samples were collected and then investigated for FVII:C (using a sensitive method and human recombinant thromboplastin as the reagent), FVII antigen, activated FVII coagulant activity (FVIIa:C) and the free-form of tissue factor pathway inhibitor.
RESULTS: None of these tests could be used as highly accurate predictors of bleeding. Nevertheless, both FVII:C and FVIIa:C differed significantly between the two clinical groups. Using ROC-curve analysis, two critical values of 8% and 3mIU/mL for FVII:C and FVIIa:C, respectively, could be proposed to discriminate between severe bleeders and non-or-mild bleeders. INTERPRETATION AND
CONCLUSIONS: A highly accurate diagnostic test for predicting bleeding tendency in inherited FVII deficiency still eludes definition, highlighting the fact that factors other than FVII itself interfere with the expression of bleeding phenotypes in this condition. Nevertheless, potential critical values using sensitive FVII:C and FVIIa:C methods may be useful in clinical laboratories for FVII-deficient patients. Those patients with FVII:C levels higher than 8% FVII:C or FVIIa:C higher than 3 mIU/mL, with no other hemostatic defect, seem to have a minimal risk of severe bleeding. Extended clinical studies are needed to support these findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194538

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  N-Glycan-calnexin interactions in human factor VII secretion and deficiency.

Authors:  Hao Wang; Lina Wang; Shuo Li; Ningzheng Dong; Qingyu Wu
Journal:  Int J Biochem Cell Biol       Date:  2019-06-08       Impact factor: 5.085

2.  Direct oral anticoagulants in factor VII deficiency patient.

Authors:  Fulvio Pomero; Laura Spadafora; Salvatore D'Agnano; Francesco Dentali; Luigi Maria Fenoglio
Journal:  Intern Emerg Med       Date:  2019-09-16       Impact factor: 3.397

3.  Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.

Authors:  Thomas J Cramer; Kristin Anderson; Karanjia Navaz; Justin M Brown; Laurent O Mosnier; Annette von Drygalski
Journal:  Blood Cells Mol Dis       Date:  2015-11-10       Impact factor: 3.039

Review 4.  Blood coagulation factor XII--a neglected player in stroke pathophysiology.

Authors:  Mirko Pham; Guido Stoll; Bernhard Nieswandt; Martin Bendszus; Christoph Kleinschnitz
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

5.  Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma.

Authors:  Jayadev M Umakanthan; Prajwal Dhakal; Krishna Gundabolu; Scott A Koepsell; Muhamed Baljevic
Journal:  Maedica (Bucur)       Date:  2018-03

6.  The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients.

Authors:  Marc C Hansel; Roberto Gramignoli; Kristen J Skvorak; Kenneth Dorko; Fabio Marongiu; William Blake; Julio Davila; Stephen C Strom
Journal:  Curr Protoc Toxicol       Date:  2014-11-06

Review 7.  Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.

Authors:  Mariasanta Napolitano; Sergio Siragusa; Guglielmo Mariani
Journal:  J Clin Med       Date:  2017-03-28       Impact factor: 4.241

8.  Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy.

Authors:  Molham Abdulsamad; Pavithra Reddy; Suvarna Guvvala; Anil Dev
Journal:  Gastroenterology Res       Date:  2017-04-19

Review 9.  Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.

Authors:  Shilpa Jain; Jennifer Donkin; Mary-Jane Frey; Skye Peltier; Sriya Gunawardena; David L Cooper
Journal:  J Blood Med       Date:  2018-11-19

10.  Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report.

Authors:  Xiong Wang; Ning Tang; Wei Chang; Yanjun Lu; Dengju Li
Journal:  BMC Med Genet       Date:  2018-09-12       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.